{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:01:05Z","timestamp":1783720865177,"version":"3.55.0"},"reference-count":32,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020124","name":"Seagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Evaluate real\u2010world epidemiologic trends and treatment patterns in newly diagnosed patients with locally advanced or metastatic urothelial carcinoma (la\/mUC) in Japan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective analysis included adults with newly diagnosed la\/mUC in Japan (January 2015\u2013December 2019) from a nationwide\u2010linked electronic medical record Diagnostic Procedure Combination claims dataset. Outcomes included epidemiologic trends (incidence and prevalence), baseline demographics, clinical characteristics, and treatment patterns in newly diagnosed patients with la\/mUC before (2015\u20132017) and after (2018\u20132019) approval of pembrolizumab in Japan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 975 patients included, 76.4% were men; 71.6% were aged 70\u2009years or older. Most cases (70.5%) were of the bladder. Between 2015 and 2019, the annual age\u2010adjusted incidence increased from 6.8 to 12.4 per 100\u2009000; the annual age\u2010adjusted period prevalence increased from 13.0 to 25.2 per 100\u2009000; and 307 (31.5%) and 668 (68.5%) patients were diagnosed from 2015 to 2017 and 2018 to 2019, respectively. Overall, 731 (75%) patients received systemic anticancer therapy; all received 1 line and 50.2% received 2 lines of therapy; 78.3% of patients received gemcitabine plus platinum\u2010based therapy and 2.2% received pembrolizumab as first\u2010line treatment. First\u2010line treatment rates increased from 69.4% to 77.5% after pembrolizumab approval. Of 367 patients who received second\u2010line treatment, 22.3% received gemcitabine plus platinum\u2010based therapy; 14.7% received pembrolizumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In the Japanese regions considered, incidence and prevalence of newly diagnosed la\/mUC increased over time and first\u2010line treatment with pembrolizumab increased after approval.<\/jats:p><\/jats:sec>","DOI":"10.1111\/iju.15450","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T07:09:10Z","timestamp":1710227350000},"page":"730-738","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real\u2010world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan"],"prefix":"10.1111","volume":"31","author":[{"given":"Keiko","family":"Asakawa","sequence":"first","affiliation":[{"name":"Department of Global Medical Affairs Japan Astellas Pharma, Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miina","family":"Waratani","sequence":"additional","affiliation":[{"name":"Department of Global Medical Affairs Japan Astellas Pharma, Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Massey","sequence":"additional","affiliation":[{"name":"Secondary Data Evidence Generation, Adelphi Real World  Bollington UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Holbrook","sequence":"additional","affiliation":[{"name":"Secondary Data Evidence Generation, Adelphi Real World  Bollington UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Global Medical Affairs Japan Astellas Pharma, Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Global Medical Affairs Japan Astellas Pharma, Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Urology Tsukuba University  Tsukuba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"e_1_2_14_2_1","unstructured":"FerlayJ ErvikM LamF LaversanneM ColombetM MeryL et\u00a0al.Global cancer observatory: cancer today.2020Available from:https:\/\/gco.iarc.fr\/today"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-019-0208-0"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13376"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001305"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-009-0383-3"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.1203"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28050325"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.5534"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30040277"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3068"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.10.017"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.012"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-022-02815-w"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S135157"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14210"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-018-1260-0"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.001"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.07.062"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-2108"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.08.127"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.08.016"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyw005"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000511667"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0298"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050312118783011"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1591424"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.20285"},{"key":"e_1_2_14_31_1","first-page":"163","article-title":"Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi\u2010institutional experience","volume":"46","author":"Kikuchi E","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14861"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-43901-5"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.15450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T05:27:26Z","timestamp":1738042046000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.15450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1111\/iju.15450"],"URL":"https:\/\/doi.org\/10.1111\/iju.15450","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"assertion":[{"value":"2023-09-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}